IN8BIO, INC.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
INAB$0.94+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Changes in Stockholders’ Equity
(In thousands, except share data)
| Common Stock(1) · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance at December 31, 2023 | 1,442,929 | $4 | $116,152 | $(91,219) | $24,937 |
| Issuance of common stock, net of issuance costs | 115,972 | — | 3,816 | - | 3,816 |
| Issuance of private placement common stock, net of issuance costs | 666 | — | 25 | - | 25 |
| Issuance of common stock, net of issuance costs | 856,499 | 3 | 6,124 | - | 6,127 |
| Issuance of private placement common stock, net of issuance costs | — | — | 5,099 | - | 5,099 |
| Issuance of private placement warrants, net of issuance costs | — | — | (89) | - | (89) |
| Stock-based compensation expense | — | — | 5,000 | - | 5,000 |
| Net loss | — | — | — | (30,437) | (30,437) |
| Balance at December 31, 2024 | 2,416,066 | $7 | $136,127 | $(121,656) | $14,478 |
| Issuance of common stock, net of issuance costs | 1,865,253 | 3 | 8,563 | - | 8,566 |
| Issuance of common stock upon exercise of Series A, B and C warrants, net of issuance costs | 357,784 | — | 2,264 | - | 2,264 |
| Issuance of private placement common stock, net of issuance costs | 5,127,029 | — | 18,501 | - | 18,501 |
| Stock-based compensation expense | — | — | 3,189 | - | 3,189 |
| Net loss | — | — | — | (19,440) | (19,440) |
| Balance at December 31, 2025 | 9,766,132 | $10 | $168,644 | $(141,096) | $27,558 |
(1)All share amounts and per share amounts disclosed in this Annual Report on Form 10-K have been restated to reflect a one-for-thirty reverse stock split effected in June 2025. See Note 1, Organization and Nature of Operations, for details.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.